June 13th, 2017

Artificial Intelligence – drug development – NYC MedTech program

Tuesday, June 13th

at the New York offices of  Troutman Sanders LLP,
Please note new address – 875 Third Avenue

Keynote Presentation:

Alix M. Lacoste

Data Scientist & Subject Matter Expert, Watson for Life Sciences 

Facing an ever increasing avalanche of data and complexity, life science organizations need faster, better, well curated information to pinpoint their focus and speed discovery and time to market of safe and effective therapies. IBM Watson Health aims to empower leaders, advocates and influencers in health through support that helps them achieve remarkable outcomes. Watson for Drug Discovery can accelerate the drug discovery process by helping researchers uncover patterns and signals hidden in data to make non-obvious and orthogonal connections.

Corporate Presenters:

Avanlee Okragly, Vice President

Simplec, LLC

SimpleC is a science based technology company that designs and delivers media-based behavioral therapies, presented as storyboards, to engage individuals. SimpleC help people maintain a healthy daily cadence by prompting for important daily activities, improving motivation through positive reflection and, if needed, specialized behavioral support.

 Neel S. Madhukar, CEO

Forbes 30 under 30

OneThree Biotech

OneThree Biotech uses artificial intelligence to identify the mechanisms and downstream clinical effects of drugs in development. Target deconvolution is crucial for understanding mechanisms of action, side-effects, designing better clinical trials, and obtaining regulatory approval, however current efforts can take up to 5 years per compound. OneThree’s proprietary platform identifies drug binding targets and any corresponding side-effects with 90% accuracy in a fraction of the time. .


About The Author